SIMCERE PHARMA (02096) gained nearly 3%, rising 2.58% to HK$12.7 with trading volume of HK$55.63 million as of press time.

On the news front, according to SIMCERE PHARMA's official announcement, the group's anti-tumor innovative drug subsidiary Zaimingen announced that its self-developed anti-tumor drug candidate SIM0508, a DNA polymerase θ (Polθ) small molecule inhibitor, has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials in combination with olaparib for treating advanced solid tumors.

According to the introduction, SIM0508 represents the latest achievement in anti-tumor "synthetic lethality" mechanisms, developed independently by Zaimingen, and is China's first Polθ inhibitor approved to enter clinical research. SIM0508 has obtained IND approvals in both China and the United States and is currently in Phase I clinical trials.

Early clinical studies show that SIM0508 demonstrates good safety and tolerability profiles with no significant hematological toxicity observed, indicating a lower risk of additive hematological toxicity when combined with PARP inhibitors or chemotherapy drugs. This suggests potential as an innovative anti-cancer therapy for treating multiple HRD solid tumors. Related research data will be published at future academic conferences.